Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer
- PMID: 38213299
- DOI: 10.1158/2159-8290.CD-23-1230
Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer
Abstract
To date, immune targeting agents have provided limited benefits in patients with metastatic prostate cancer. Bispecific T-cell engagers, especially targeting STEAP1, have shown encouraging results in preclinical and phase I studies and thus represent a novel and promising treatment option in this setting. See related article by Nolan-Stevaux et al., p. 90 (7). See related article by Kelly et al., p. 76 (8).
©2023 American Association for Cancer Research.
Comment on
-
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290.CD-23-0984. Cancer Discov. 2024. PMID: 37861452
-
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964. Cancer Discov. 2024. PMID: 37861461 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
